[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584460":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":31,"responsibleParty":48,"collaborators":20,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":20,"enrollmentInfo":61,"targetDuration":20,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":20,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Changhai Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Immediate GC chemotherapy infusion","EXPERIMENTAL","For enrolled patients receiving immediate cisplatin\u002Fgemcitabine chemotherapy via intravenous infusion within 24 hours post transurethral resection of bladder tumor (TURBT), fluid samples were collected before and after TURBT, as well as post-chemotherapy, for UroCAD testing to assess chromosomal instability status and evaluate postoperative tumor residual changes. Subsequently, following EAU guidelines, patients were administered 1 year of intravesical Bacillus Calmette-Guérin (BCG) induction and maintenance therapy, with regular imaging studies and cystoscopic examinations for follow-up to assess the patients' pathological response status.",[13],"Procedure: Immediate postoperative chemotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","Immediate postoperative chemotherapy","Systemic chemotherapy with cisplatin\u002Fgemcitabine intravenous infusion within 24 hours after TURBT",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Shuxiong Zeng, M.D. Ph.D","Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China","PRINCIPAL_INVESTIGATOR",[27],{"name":23,"role":28,"phone":29,"phoneExt":29,"email":30},"CONTACT","+8618930568759","zengshuxiong@126.com",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Shanghai Changhai Hospital","RECRUITING","Shanghai","Shanghai Municipality","200000","China","CN",{"type":41,"coordinates":42},"Point",[43,44],121.45806,31.22222,{"lat":44,"lon":43},[47],{"name":23,"role":28,"phone":29,"phoneExt":29,"email":30},{"type":25,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Shuxiong Zeng","A.P","100584460","immediate-chemotherapy-following-resection-for-high-risk-non-muscle-invasive-bladder-cancer-100584460",false,"NCT06889623","Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer","Impact of Immediate Cisplatin\u002FGemcitabine Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer: an Open-label, Single-arm, Prospective Trial","HIGCrecur","Inclusion Criteria:\n\n* Patients with a history and cystoscopy results indicating high-risk NMIBC:\n\n  * High-grade T1\n  * Any recurrent high-grade Ta\n  * High-grade Ta \\& Tumor diameter greater than 3 cm or multifocal\n  * Any CIS\n  * Any BCG failure in patients with high-grade disease\n  * Any variant histology\n  * Any LVI\n  * Any high-grade prostatic urethral involvement\n* Patients in generally good condition with a follow-up period of 2 years\n\nExclusion Criteria:\n\n* Bladder cancer other than UC\n* MIBC or benign diseases\n* Incomplete tumor resection\n* Active infection\n* Concurrent upper urinary tract or prostatic urethral UC\n* Previous systemic chemotherapy, immunotherapy, or radiotherapy\n* Leukopenia\u002Fthrombocytopenia\n* Serum creatinine greater than twice the normal level\n* Uncontrollable urinary tract infection","ALL","18 Years",{"count":62,"type":63},72,"ESTIMATED","INTERVENTIONAL",[66],"NA","Residual tumors after transurethral resection of bladder tumors (TURBT) range from 17-70%, and floating tumor cells from traditional segmental resection may lead to recurrence if they re-implant in the bladder wall. Immediate systemic chemotherapy post-surgery aims to eliminate microlesions promptly and minimize recurrence risk, yet its safety and efficacy require further exploration. This prospective, single-arm study delves into evaluating the efficacy and safety of immediate postoperative systemic chemotherapy in patients with suspected high-risk non-muscle-invasive bladder cancer.",[69],"NMIBC","2025-03-16",{"date":72,"type":73},"2025-03-21","ACTUAL",{"date":75,"type":73},"2024-06-01",{"date":77,"type":63},"2028-06-01",{"name":5,"class":6},1]